R&D forms the backbone of IDPL, aiding it to keep abreast with the modern technologies of the world and enabling it to build self-reliance to meet the health needs of India.

IDPL has 2 R&D Centres at Hyderabad and Rishikesh with large animal houses. These Centres endeavour to create import substitute, improve and update technologies, develop new drugs and formulations and high yielding strains for antibiotics. There are hardly any technologies in original product-mix of company which have not been improved upon.

A measure of its success lies in the production of Vitamin B6 for the first time in the country based exclusively on IDPL’s technology. In-house R&D had also succeeded in developing and implementing technologies for production of Methyl Dopa and Chloroquine Phosphate.

Three novel compounds, having promising therapeutic value, are in advanced stage of biological evaluation. A non-steroidal, anti-inflammatory and anti-arthritic compound has completed Phase-III clinical trials.

In addition, IDPL has presently a Formulations Development Research Laboratory at Rishikesh plant. A number of company’s formulations have been developed through in-house formulations development research.